路平制药（LPC）：鲁宾公司（LPC IN）买入及时在美国推出产品是维持增长的关键
Hui Feng Yin Hang·2025-05-16 05:45
Lupin (LPC IN) Buy: Timely US launches key to sustain growth Operationally in-line 4Q: Revenue at INR56.7bn (+14.2% y-o-y) was in line with HSBCe. India segment sales at INR17.1bn (c31% of 4Q) grew 6.9% y-o-y and Lupin expects its prescription (Rx) business (more than 90% of India sales) to continue to grow at 1.2-1.3x vs the market. US sales at USD245m (c41% of 4Q) grew 17.2% y-o-y in constant currency, helped by the launch of gPred Forte and traction in mirabegron. Gross margin at 69.7% improved 184bp y-o ...